Last reviewed: June 28, 2026
Last updated: June 28, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Mounjaro and Zepbound represent the same medication—tirzepatide—approved by the FDA for different purposes: diabetes management and chronic weight management, respectively. Both activate GLP-1 and GIP receptors, hormonal pathways that regulate appetite, blood sugar, and metabolism. Clinical trials show participants using tirzepatide lost 20–22% of body weight over 68 weeks, making it one of the most effective weight loss medications available today.
Understanding Tirzepatide: The Active Ingredient in Both Medications
Tirzepatide is a synthetic peptide that mimics two natural hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones regulate hunger signals in the brain, slow stomach emptying, and improve insulin sensitivity. By binding to both receptor types simultaneously, tirzepatide produces stronger appetite suppression and metabolic benefits than single-receptor drugs like semaglutide (Ozempic or Wegovy).
The SURPASS clinical trial program demonstrated that tirzepatide outperforms semaglutide in weight loss outcomes. Participants receiving the highest tirzepatide dose lost an average of 22.5% body weight, compared to 17.4% for high-dose semaglutide. This dual-action mechanism makes tirzepatide an attractive option for people seeking maximum results, though individual response varies based on genetic factors, lifestyle, and baseline metabolic health.
Mounjaro vs Zepbound: Key Differences and Similarities
Mounjaro received FDA approval in 2022 for type 2 diabetes management and carries a therapeutic indication for blood sugar control. Zepbound gained approval in 2023 specifically for chronic weight management in adults with obesity or overweight status with weight-related complications. Despite these regulatory labels, both products contain identical tirzepatide formulations and are prescribed off-label across indications based on patient need and physician judgment.
Practical differences are minimal from a clinical standpoint. Both are injected once weekly, both use the same dose-escalation protocol starting at 2.5 mg, and both demonstrate comparable safety and tolerability profiles. Insurance coverage, prior authorization requirements, and patient out-of-pocket costs may vary depending on whether a claim is filed under the diabetes or weight-loss indication, making consultation with your healthcare provider essential for financial planning.
Clinical Evidence: Weight Loss Results and Timeline
The SURMOUNT-4 trial evaluated Zepbound specifically for weight loss and found that 85% of participants achieved at least 5% weight reduction, while 60% achieved 15% or greater weight loss. Participants typically notice appetite suppression and early weight loss within 2–4 weeks, though maximum benefit appears by 16–20 weeks of consistent dosing. Continued weight loss is observed over 68 weeks with adherence to the medication and lifestyle modifications including reduced calorie intake and regular physical activity.
Individual outcomes depend on several factors: baseline weight, metabolic rate, adherence to dosing schedules, dietary compliance, and genetic predisposition to GLP-1 and GIP receptor function. Some people respond robustly to tirzepatide while others experience more modest benefits. Genetic variation in GLP1R and GIPR genes influences how efficiently your body responds to these medications, which is why personalized assessment can optimize treatment selection and dose timing.
Choosing Between Mounjaro, Zepbound, and Compounded Tirzepatide
Brand-name Mounjaro and Zepbound offer pharmaceutical-grade reliability and direct manufacturer support, but typically carry higher out-of-pocket costs, especially without insurance coverage. PlexusDx offers compounded tirzepatide injection from licensed 503A pharmacies at a starting price of $249 per month, with the same active ingredient and proven efficacy at a fraction of retail brand pricing. Compounded versions are manufactured under strict pharmaceutical quality standards and remain HSA/FSA eligible, making them accessible for patients across all 50 states without membership fees.
The choice between brand and compounded tirzepatide should prioritize clinical outcome and personal financial circumstances rather than brand perception. Both contain tirzepatide; both require physician oversight and regular monitoring. PlexusDx patients benefit from personalized genetic testing (Precision Peptide Genetic Test, $99 add-on) that maps 14 metabolic pathways and 49 peptides to predict your individual response to GLP-1 and GIP therapies, helping your provider optimize dosing and medication selection from the outset.
Side Effects and Safety Considerations
Tirzepatide is generally well-tolerated, with nausea, vomiting, and diarrhea being the most commonly reported side effects, especially during dose escalation. Most gastrointestinal effects diminish within 1–2 weeks as the body adapts. Rare but serious risks include acute pancreatitis, gallbladder disease (related to rapid weight loss), and thyroid concerns; these require immediate medical attention and baseline screening before starting therapy.
Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2) should not use tirzepatide due to animal study signals of thyroid C-cell tumors. Pregnancy is contraindicated due to developmental concerns; women of childbearing age should use effective contraception. Regular check-ins with your provider—ideally monthly during dose escalation—ensure early detection of adverse effects and allow dose adjustment or medication discontinuation if needed.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Zepbound more effective than Mounjaro for weight loss?
Both contain identical tirzepatide and produce the same weight loss outcomes in clinical trials. Zepbound carries the weight-loss indication while Mounjaro targets diabetes; the medication itself performs identically for weight management. Your individual results depend on genetic factors, lifestyle adherence, and baseline health status rather than brand selection.
What is the difference between tirzepatide and semaglutide?
Tirzepatide activates two receptors (GLP-1 and GIP), while semaglutide activates only GLP-1. Clinical trials show tirzepatide produces 22% average body weight loss versus 17% for semaglutide, making it more potent. Tirzepatide may also provide superior metabolic benefits, though both are effective GLP-1 therapies.
How much does tirzepatide cost at PlexusDx?
PlexusDx compounded tirzepatide injection starts at $249 per month across all commitment tiers, with no flat per-compound pricing increases—your dose may go up, but your price won't. The medication is HSA/FSA eligible, available in all 50 states, and requires no membership or insurance.
Are compounded tirzepatide and brand-name versions equally safe?
PlexusDx tirzepatide is compounded by licensed 503A pharmacies meeting stringent FDA quality standards identical to those for brand medications. Both contain the same active ingredient and demonstrate equivalent safety and efficacy. The primary difference is cost and accessibility rather than clinical performance or safety profile.
Can genetic testing help predict my tirzepatide response?
Yes. PlexusDx Precision Peptide Genetic Test ($99 add-on) analyzes key variants in GLP1R, GIPR, FTO, and MC4R genes across 14 metabolic pathways to predict your individual response to tirzepatide and other GLP-1 therapies. This personalized insight helps your provider optimize dosing and medication selection from the start.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Managing Heart Health: Does Wegovy Help Blood Pressure?
What to Expect After Your First Zepbound Injection